drugset / Trial / NCT04989699
Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration
RandomizedParallel-groupTriple-blindTreatment
Summary
Evaluate the safety, tolerability, and efficacy of OTX-TKI for intravitreal use in subjects with Neovascular Age-Related Macular Degeneration
Timeline
- Start
- 2021-07-28
- Primary completion
- 2023-02-06
- Completion
- 2023-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | — | — |
| Comparator | OTX-TKI | Small molecule | — | Intravitreal |